Vaccibody AS
Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies for the treatment of cancer and autoimmune diseases. The company develops vaccines for the treatment cancer, autoimmune, and infectious diseases. Its lead product candidates include VB10.NEO, a cancer neoantigen vaccine, which is in phase I/IIa clinical trial for the treatment of local… Read more
Market Cap & Net Worth: Vaccibody AS (5VB)
Vaccibody AS (F:5VB) has a market capitalization of $76.49 Million (€74.52 Million) as of March 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #22595 globally and #2453 in its home market, demonstrating a -6.01% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Vaccibody AS's stock price €0.23 by its total outstanding shares 326546444 (326.55 Million).
Vaccibody AS Market Cap History: 2021 to 2026
Vaccibody AS's market capitalization history from 2021 to 2026. Data shows change from $2.63 Billion to $76.49 Million (-51.59% CAGR).
Vaccibody AS Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Vaccibody AS's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
8.46x
Vaccibody AS's market cap is 8.46 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $2.63 Billion | $33.96 Million | -$9.41 Million | 77.57x | N/A |
| 2022 | $873.51 Million | $7.17 Million | -$42.74 Million | 121.86x | N/A |
| 2023 | $608.04 Million | $12.90 Million | -$35.15 Million | 47.13x | N/A |
| 2024 | $73.41 Million | $8.68 Million | -$38.82 Million | 8.46x | N/A |
Competitor Companies of 5VB by Market Capitalization
Companies near Vaccibody AS in the global market cap rankings as of March 19, 2026.
Key companies related to Vaccibody AS by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Vaccibody AS Historical Marketcap From 2021 to 2026
Between 2021 and today, Vaccibody AS's market cap moved from $2.63 Billion to $ 76.49 Million, with a yearly change of -51.59%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €76.49 Million | +44.80% |
| 2025 | €52.83 Million | -28.04% |
| 2024 | €73.41 Million | -87.93% |
| 2023 | €608.04 Million | -30.39% |
| 2022 | €873.51 Million | -66.84% |
| 2021 | €2.63 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Vaccibody AS was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $76.49 Million USD |
| MoneyControl | $76.49 Million USD |
| MarketWatch | $76.49 Million USD |
| marketcap.company | $76.49 Million USD |
| Reuters | $76.49 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.